Latest Articles

Publication Date
All News Scientific
Cyclana Bio granted Health Research Authority approval and recruits first patients for clinical observational study in endometriosis - News-Medical

Cyclana Bio granted Health Research Authority approval and recruits first patients for clinical observational study in endometriosis News-Medical

Published: May 19, 2026, 12:42 p.m.
Read Full Article
Cyclana Bio Granted Health Research Authority Approval and Recruits First Patients for Clinical Observational Study in Endometriosis - BioSpace

Cyclana Bio Granted Health Research Authority Approval and Recruits First Patients for Clinical Observational Study in Endometriosis BioSpace

Published: May 19, 2026, 11:15 a.m.
Read Full Article
FinancialContent - Cyclana Bio Granted Health Research Authority Approval and Recruits First Patients for Clinical Observational Study in Endometriosis - FinancialContent

FinancialContent - Cyclana Bio Granted Health Research Authority Approval and Recruits First Patients for Clinical Observational Study in Endometriosis FinancialContent

Published: May 19, 2026, 9:06 a.m.
Read Full Article
Merck's drug helps uterine cancer patients live longer in late-stage trial - Reuters

Merck's drug helps uterine cancer patients live longer in late-stage trial Reuters

Published: May 18, 2026, 2 p.m.
Read Full Article
Merck announces trial results for ADC that addresses unmet needs for patients with advanced endometrial cancer - PharmaLive

Merck announces trial results for ADC that addresses unmet needs for patients with advanced endometrial cancer PharmaLive

Published: May 18, 2026, 1:38 p.m.
Read Full Article
The Evolving Role of the Pharmacist: From Clinical Pathways to Patient Advocacy - Pharmacy Times

The Evolving Role of the Pharmacist: From Clinical Pathways to Patient Advocacy Pharmacy Times

Published: May 18, 2026, 12:19 p.m.
Read Full Article
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Business Wire

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Business Wire

Published: May 18, 2026, 10:45 a.m.
Read Full Article
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer - Yahoo! Finance Canada

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer Yahoo! Finance …

Published: May 18, 2026, 10:45 a.m.
Read Full Article
PCOS gets a new name after 14 years of research and patient advocacy - LEX18

PCOS gets a new name after 14 years of research and patient advocacy LEX18

Published: May 14, 2026, 10:05 a.m.
Read Full Article
PCOS gets a new name after 14 years of research and patient advocacy - LEX 18 News

PCOS gets a new name after 14 years of research and patient advocacy LEX 18 News

Published: May 13, 2026, 11:05 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!